Starpharma DEP - Docetaxel

FromStarpharma Holdings Limited

SHARE

DEP® docetaxel is an enhanced version of docetaxel (Taxotere®) – widely used for breast, lung & prostate cancer. Docetaxel (Taxotere®) is a commonly used chemotherapy agent despite having multiple US FDA “Black Box” warnings. DEP® docetaxel is a detergent free, aqueous formulation of docetaxel.

Most popular related searches

preclinical trial

therapeutic potential

tumor targeting

chemotherapy agents

chemotherapy agent

The advantages* of DEP® docetaxel include:

Reduction in neutropenia
Tumour-targeting (~70x more); improved efficacy
No steroid pre-treatment
Improved pharmacokinetics

Clinical studies have demonstrated reduction in important side effects with DEP® including bone marrow toxicity, anaphylaxis, oedema, and hair-loss.

DEP® docetaxel has patent filings to 2032 (plus up to an additional ~5 years).

*Multiple preclinical studies have established improved efficacy, survival, and safety with DEP® with many different drugs.

Superiority to docetaxel/Taxotere® alone across multiple cancer types

In xenograft studies DEP® docetaxel demonstrated a significant enhancement of anticancer effect when compared to docetaxel/Taxotere® alone. Furthermore, in the study 60% of animals treated with DEP® docetaxel had no evidence of tumours at 94 days - whereas 100% of the docetaxel treated mice showed significant tumour re-growth or recurrence at the same time point.